Economic Times | Novartis heart failure drug gets FDA incentives Bioscience Technology Novartis said patients treated with serelaxin in a late-stage trial were 37 percent less likely to die in the six months after a heart failure episode compared with patients who received standard treatment. The FDA created the breakthrough therapy ... FDA grants Breakthrough Therapy designation to Novartis' serelaxin (RLX030 ... US FDA deems Novartis' heart failure candidate a 'breakthrough' Novartis Heart-Failure Drug Wins 'Breakthrough' Status at FDA |
